|
Immuron Chairman Transition
|
30 June 2023 at 11:25am
|
|
Letter to Shareholders
|
22 June 2023 at 8:55am
|
|
Immuron CEO, Steven Lydeamore presents at LD Micro
|
7 June 2023 at 8:50am
|
|
Immuron Initiates Recruitment of Travelan Clinical Study
|
30 May 2023 at 2:25pm
|
|
FDA Removed Clinical Hold on Campylobacter ETEC Therapeutic
|
8 May 2023 at 9:20am
|
|
IMC CEO Steven Lydeamore to present at Coffee Microcaps
|
2 May 2023 at 8:40am
|
|
Q3 FY23 Business Update Presentation
|
19 April 2023 at 9:40am
|
|
Q3 FY23 Business Update Webinar
|
11 April 2023 at 10:40am
|
|
Immuron Q3 Sales reach 150% of 1H Sales
|
6 April 2023 at 8:50am
|
|
Notification of cessation of securities - IMC
|
16 March 2023 at 5:25pm
|
|
Appendix 4D and Half Year Report
|
28 February 2023 at 7:25pm
|
|
Business Update Presentation
|
28 February 2023 at 10:15am
|
|
Immuron CEO Steven Lydeamore to host investor webinar
|
15 February 2023 at 8:25am
|
|
Immuron and US NMRC respond to CampETEC FDA Clinical Hold
|
25 January 2023 at 9:55am
|
|
US DOD Travelan Clinical Recruitment Milestone
|
18 January 2023 at 2:35pm
|
|
Immuron Receives European Patent on Drug Composition
|
17 January 2023 at 10:10am
|
|
Change in substantial holding
|
30 December 2022 at 8:45am
|
|
Immuron Receives FDA Approval for Travelan IND Application
|
23 December 2022 at 10:10am
|
|
Immuron Submits IND Application To FDA for Travelan
|
5 December 2022 at 8:55am
|
|
Amended Constitution
|
1 December 2022 at 2:45pm
|
|
Results of Annual General Meeting
|
21 November 2022 at 7:25pm
|
|
AGM Presentation
|
21 November 2022 at 9:35am
|
|
Immuron completes strategic investment in Ateria Health
|
16 November 2022 at 10:10am
|
|
Immuron CEO Steven Lydeamore to present at AusBioInvest
|
26 October 2022 at 10:15am
|
|
Notice of Annual General Meeting/Proxy Form
|
21 October 2022 at 10:10am
|
|
IMC investment in leading gut health biotech Ateria Health
|
13 October 2022 at 12:15pm
|
|
Immuron Executes Travelan Clinical Trial Agreement Pharmaron
|
4 October 2022 at 12:25pm
|
|
Appendix 4G
|
9 September 2022 at 5:20pm
|
|
Corporate Governance Statement
|
9 September 2022 at 5:20pm
|
|
Annual Report to shareholders
|
9 September 2022 at 5:20pm
|
|
FY22 Results and Business Update Presentation
|
31 August 2022 at 9:59am
|
|
Appendix 4E and Preliminary Final Report
|
31 August 2022 at 9:50am
|
|
Immuron CEO, Steven Lydeamore, to host an investor webinar
|
29 August 2022 at 9:59am
|
|
Immuron Update on IMM-124E SARS-CoV-2 Research
|
19 August 2022 at 9:50am
|
|
Update on IND Application for Campylobacter ETEC Therapeutic
|
26 July 2022 at 1:00pm
|
|
North American Travelan Sales up 494%, Global sales up 431%
|
11 July 2022 at 9:25am
|
|
European Patent Notification on Drug Composition for CDI
|
7 July 2022 at 8:45am
|
|
Change of Director's Interest Notice (DP)
|
4 July 2022 at 12:30pm
|
|
Notification regarding unquoted securities - IMC
|
1 July 2022 at 5:50pm
|
|
Change of Director's Interest Notice
|
15 June 2022 at 12:10pm
|
|
Notification of cessation of securities - IMC
|
14 June 2022 at 11:45am
|
|
Notification of cessation of securities - IMC
|
10 June 2022 at 4:05pm
|
|
Change in substantial holding
|
25 May 2022 at 8:45am
|
|
US DoD NMRC files IND application with FDA
|
11 May 2022 at 3:05pm
|
|
US DoD Uniformed Services University Clinical Update
|
9 May 2022 at 11:59am
|
|
Appointment of Mr Steven Lydeamore as Chef Executive Officer
|
5 May 2022 at 6:55pm
|
|
Immuron Q3 Global Sales up 216% YoY
|
27 April 2022 at 10:15am
|
|
Immuron new MTEC project proposal
|
19 April 2022 at 10:55am
|
|
Initial Director's Interest Notice
|
16 March 2022 at 6:15pm
|
|
Appointment of Paul Brennan as Non-Executive Director
|
16 March 2022 at 9:55am
|
Immuron